Avantor Inc Revenue Growth Rates (AVTR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Avantor Inc   (NYSE: AVTR)
 

AVTR's Revenue Growth by Quarter and Year

Avantor Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AVTR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 1,581.40
FY 1,581.40

AVTRs Annual Revenue
Avantor Inc 's Revenue in the fiscal year 2025 $ 6,552.20 millions
Avantor Inc 's Revenue in the fiscal year 2024 $ 6,783.60 millions
Avantor Inc 's Revenue in the fiscal year 2023 $ 6,967.20 millions
Avantor Inc 's Revenue in the fiscal year 2022 $ 7,512.40 millions
Avantor Inc 's Revenue in the fiscal year 2020 $ 7,386.10 millions




AVTR Revenue first quarter 2026 Y/Y Growth Comment
Avantor Inc announced in the first quarter 2026 Revenue of $ 1,581.40 millions equally to same quarter a year ago.Avantor Inc reported no change in Revenue in the first quarter 2026 by 0% to $ 1,581.40 millions, from the same quarter in 2025.

Looking into first quarter 2026 results within Laboratory Analytical Instruments industry 15 other companies have achieved higher Revenue growth. While Avantor Inc ' s Revenue no change of 0% ranks overall at the positon no. 2791 in the first quarter 2026.


AVTR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -1.36 % -2.1 % -4.02 %
3rd Quarter September - -5.28 % -0.34 % -7.34 %
2nd Quarter June - -1.14 % -2.36 % -8.72 %
1st Quarter March 0 % -5.86 % -5.65 % -8.72 %
FY   - -3.41 % -2.64 % -

Financial Statements
Avantor Inc 's first quarter 2026 Revenue $ 1,581.40 millions AVTR's Income Statement
Avantor Inc 's first quarter 2025 Revenue $ 1,581.40 millions Quarterly AVTR's Income Statement


AVTR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 2.45 % -1.62 % 0.15 %
3rd Quarter September - -3.54 % 0.68 % -1.36 %
2nd Quarter June - 6.45 % 1.37 % -2.04 %
1st Quarter March -4.94 % -6.24 % -2.5 % -0.82 %
FY (Year on Year)   - -3.41 % -2.64 % -


Back to AVTR Growth rate Comparisons >> Back to AVTR Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #16
Healthcare Sector #397
Overall #2791

Revenue Y/Y Growth Statistics
High Average Low
25.69 % 1.86 % -8.72 %
(Jun 30 2021)   (Sep 30 2023)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #16
Healthcare Sector #397
Overall #2791
Revenue Y/Y Growth Statistics
High Average Low
25.69 % 1.86 % -8.72 %
(Jun 30 2021)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Avantor Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
11.58 % 0.25 % -6.24 %
(Dec 31 2020)  


AVTR's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Avantor Inc disclosed fall in Revenue from the fourth quarter by -4.94% to $ 1,581.40 millions, from $ 1,663.60 millions achived in the previous reporting period.

But that's not important problem, as Avantor Inc 's Revenue generally seem to plunge in this quarter.

Within Laboratory Analytical Instruments industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Avantor Inc 's Revenue growth quarter on quarter, overall rank is 2044.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #6
Healthcare Sector #247
Overall #2044
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #6
Healthcare Sector #247
Overall #2044
Revenue Q/Q Growth Statistics
High Average Low
11.58 % 0.25 % -6.24 %
(Dec 31 2020)  


AVTR's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Avantor Inc disclosed fall in Revenue from the fourth quarter by -4.94% to $ 1,581.40 millions, from $ 1,663.60 millions achived in the previous reporting period.

But that's not important problem, as Avantor Inc 's Revenue generally seem to plunge in this quarter.

Within Laboratory Analytical Instruments industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Avantor Inc 's Revenue growth quarter on quarter, overall rank is 2044.


Avantor Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 6,552.20 $ 6,552.20 $ 6,575.20 $ 6,665.80 $ 6,685.20
Y / Y Revenue Growth (TTM) -1.99 % -3.41 % -3.59 % -2.34 % -2.64 %
Year on Year Revenue Growth Overall Ranking # 2355 # 615 # 1746 # 834 # 2853
Seqeuential Revenue Change (TTM) 0 % -0.35 % -1.36 % -0.29 % -1.45 %
Seq. Revenue Growth (TTM) Overall Ranking # 2275 # 569 # 1568 # 732 # 2418


Cumulative Revenue growth Comment
Avantor Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2025. If the fiscal year would end in Mar 31 2026, Avantor Inc 's annual Revenue decline would be -1.99% year on year to $6,552 millions.

In the Healthcare sector 353 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 615 to 2355.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 10
Healthcare Sector # 354
Overall # 2355

Revenue TTM Y/Y Growth Statistics
High Average Low
134.85 %
 12.93 %
-7.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 339
S&P 500 # 2275
Cumulative Revenue growth Comment
Avantor Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2025. If the fiscal year would end in Mar 31 2026, Avantor Inc 's annual Revenue decrease would be -1.99% year on year to $6,552 millions.

In the Healthcare sector 353 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 615 to 2355.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 10
Healthcare Sector # 354
Overall # 2355

Revenue TTM Y/Y Growth Statistics
High Average Low
134.85 %
12.93 %
-7.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 339
S&P 500 # 2275




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AVTR's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Avantor Inc Revenue Growth Rates (AVTR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Avantor Inc (CIK 1722482).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-050415
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Avantor Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.